What is NanoMosaic?
NanoMosaic operates at the intersection of nanotechnology and clinical diagnostics, focusing on the development of best-in-class assays for biomarker discovery. The company's core innovation, the Tessie platform, employs 1.8 billion MosaicNeedles per chip to enable full proteome interrogation. This technology allows for the detection of proteins across seven orders of dynamic range, facilitating multiplexing capabilities that were previously unattainable. By providing a label-free, high-throughput solution, NanoMosaic is effectively lowering the barrier to entry for complex proteomic studies, thereby accelerating the pace of drug discovery and precision medicine development.
How much funding has NanoMosaic raised?
NanoMosaic has raised a total of $42.8M across 2 funding rounds:
Angel/Seed
$2M
Series A
$40.8M
Angel/Seed (2021): $2M with participation from Zayn Capital, villageglobal.com, and VEF
Series A (2021): $40.8M led by Pura Vida Investments, Insight Partners, RA Capital Management, and Time BioVentures
Key Investors in NanoMosaic
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing diagnostics and research tools.
Insight Partners
A global software-focused venture capital and private equity firm that provides capital and operational support to high-growth technology companies.
Pura Vida Investments
A specialized hedge fund that invests across all sectors and stages of the healthcare industry, supporting both public and private enterprises.
What's next for NanoMosaic?
With the recent infusion of capital, NanoMosaic is expected to scale its operational capacity and expand its commercial footprint within the global life sciences market. The strategic focus will likely center on enhancing the throughput of the Tessie platform and broadening its application in clinical diagnostics. As the company transitions from early-stage development to a more mature commercial entity, it will prioritize the validation of novel biomarkers and the expansion of its intellectual property portfolio. Investors are closely monitoring the firm's ability to integrate its nanoneedle technology into standard laboratory workflows, which could establish NanoMosaic as a foundational player in the next generation of proteomic research tools.
See full NanoMosaic company page
